Oxford Biomedica, a major contract‑manufacturer for cell and gene therapy, confirmed it has engaged in takeover talks with private equity investor EQT after turning down prior unsolicited bids the board judged undervalued. The company said it has repeatedly rejected multiple offers and is in discussions to evaluate options while protecting shareholder value. The firm’s manufacturing footprint and vector production capabilities make it an attractive target as demand for regionalized cell and gene manufacturing grows. The confirmation formalizes a running takeover narrative and sets a timeline for potential deal activity or further strategic responses.